Leadership & Pay ·
Gossamer Bio appointed Gregory A. Ciongoli as a Class III director effective September 16, 2026, with his term…
GOSSGossamer Bio, Inc.
Gossamer Bio appointed Gregory A. Ciongoli as a Class III director effective September 16, 2026, with his term expiring at the 2027 annual meeting. Mr. Ciongoli also joined the Audit Committee and receives an annual cash retainer of $40,000 for board service plus $7,500 for audit committee membership. He is a founder and managing partner of Adiumentum Capital Management and previously served as a partner at Baupost Group. The appointment follows his participation in the company's August 2026 private placement PIPE transaction, where he purchased pre-funded warrants exercisable for approximately 144,024 shares of common stock post-split. Gossamer Bio is a clinical-stage biopharmaceutical company focused on developing seralutinib for pulmonary arterial hypertension and related conditions.